[Alpha Biz= Reporter Kim Jisun] ABL Bio, a biotech specializing in bispecific antibodies, announced on October 28 that it received a $5 million milestone payment (approximately 7 billion KRW) from Sanofi following the successful technology transfer of its manufacturing processes for ABL301. ABL301, designed for treating Parkinson’s disease and other neurodegenerative disorders, uses ABL Bio's "Grabody-B" platform to inhibit the buildup of alpha-synuclein, a protein linked to Parkinson’s, by efficiently delivering therapeutic antibodies across the blood-brain barrier.
The Grabody-B platform leverages IGF1R to enhance blood-brain barrier (BBB) penetration for therapeutic candidates targeting central nervous system diseases.
In January 2022, ABL Bio signed a co-development and licensing agreement with Sanofi for ABL301, a deal valued at up to $1.06 billion (around 1.46 trillion KRW). Since then, the two companies have collaborated through a joint research and development committee. The current milestone payment relates to this agreement, with ABL Bio leading ABL301’s Phase 1 clinical trials in the U.S., and Sanofi set to take over from Phase 2 onwards.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
